This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (55)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Alert me on articles by topic

Gloria Lena Vega, PhD; Myron F. Weiner, MD; Anne M. Lipton, MD; Klaus von Bergmann, MD; Dieter Lütjohann, PhD; Carol Moore, MS; Doris Svetlik, RN, MS

Arch Neurol. 2003;60:510-515.

Background  The statin treatment of dyslipidemia is associated with a reduced risk of development of Alzheimer disease (AD). The effect may be mediated by a reduction in cholesterol biosynthesis in the brain, by lowering levels of apolipoprotein E (apo E)–containing lipoproteins, or by pleitropic effects such as reduction in -amyloid production. In the brain, cholesterol from damaged or dying neurons is converted to 24S-hydroxycholesterol by cholesterol 24-hydroxylase (CYP46). The oxysterol is subsequently transferred across the blood-brain barrier, transported to the liver by low-density lipoproteins (LDLs), and excreted as bile acids. Most of plasma 24S-hydroxycholesterol is derived from brain cholesterol; consequently, plasma levels of the oxysterol reflect brain cholesterol catabolism.

Objective  To examine the effect of 3 statins and a nonstatin hypolipidemic agent on plasma levels of 24S-hydroxycholesterol and apo E in patients with AD.

Study Design  The study had a sequential parallel design. It was open-labeled and involved lipoprotein and 24S-hydroxycholesterol evaluations at baseline and at 6 weeks of treatment with 40 mg of lovastatin, simvastatin, or pravastatin sodium per day, or 1 g of extended-release niacin per day. Blood samples were drawn after a 12-hour fast for measurement of plasma sterols, oxysterols, lipoprotein cholesterol, and levels of apo E, plasma transaminases, and glucose. Measurements were made at baseline and during treatment.

Results  Statin treatment reduced levels of plasma lathosterol by 49.5%, 24S-hydroxycholesterol by 21.4%, LDL cholesterol by 34.9%, and total cholesterol by 25%. The ratios of lathosterol-campesterol and 24S-hydroxycholesterol–LDL cholesterol were reduced significantly, but the ratio of 24S-hydroxycholesterol–total cholesterol was unchanged. Extended-release niacin also significantly reduced levels of 24S-hydroxycholesterol by 10% and LDL cholesterol by 18.1%. None of the agents lowered plasma concentration of apo E.

Conclusions  Statins lowered levels of plasma 24S-hydroxycholesterol without affecting levels of apo E. The LDL lowering was more pronounced than 24S-hydroxycholesterol reductions. The effect of statins on LDL partially explains the reduction of plasma oxysterol level.

From the Departments of Clinical Nutrition (Dr Vega), Psychiatry (Drs Weiner and Lipton and Mss Moore and Svetlik), and Neurology (Dr Lipton), the Center for Human Nutrition (Dr Vega), and the Alzheimer's Disease Center (Drs Weiner and Lipton and Mss Moore and Svetlik), University of Texas Southwestern Medical Center, Dallas; Nutrition and Metabolism Laboratory, Metabolic Unit, Veterans Affairs Medical Center, Dallas (Dr Vega); and Department of Clinical Pharmacology, University of Bonn Medical Center, Bonn, Germany (Drs Bergmann and Lütjohann).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Association of statin use with cognitive decline in elderly African Americans
Szwast et al.
Neurology 2007;69:1873-1880.
ABSTRACT | FULL TEXT  

Effect of apolipoprotein e on the cerebral load of latent herpes simplex virus type 1 DNA.
Burgos et al.
J. Virol. 2006;80:5383-5387.
ABSTRACT | FULL TEXT  

Treating vascular risk factors and maintaining vascular health: Is this the way towards successful cognitive ageing and preventing cognitive decline?
Alagiakrishnan et al.
Postgrad. Med. J. 2006;82:101-105.
ABSTRACT | FULL TEXT  

Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
Lane and Farlow
J. Lipid Res. 2005;46:949-968.
ABSTRACT | FULL TEXT  

Cholesterol and apolipoprotein E in Alzheimer's disease
Reiss
AM J ALZHEIMERS DIS OTHER DEMEN 2005;20:91-96.
ABSTRACT  

Brain Cholesterol: Long Secret Life Behind a Barrier
Bjorkhem and Meaney
Arterioscler. Thromb. Vasc. Bio. 2004;24:806-815.
ABSTRACT | FULL TEXT  

Iron, Atherosclerosis, and Neurodegeneration: A Key Role for Cholesterol in Promoting Iron-Dependent Oxidative Damage?
ONG and HALLIWELL
Ann. N. Y. Acad. Sci. 2004;1012:51-64.
ABSTRACT | FULL TEXT  

Plasma Levels of {beta}-Amyloid(1-40), {beta}-Amyloid(1-42), and Total {beta}-Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins
Hoglund et al.
Arch Neurol 2004;61:333-337.
ABSTRACT | FULL TEXT  

p21-dependent Inhibition of Colon Cancer Cell Growth by Mevastatin Is Independent of Inhibition of G1 Cyclin-dependent Kinases
Ukomadu and Dutta
J. Biol. Chem. 2003;278:43586-43594.
ABSTRACT | FULL TEXT  

Cholesterol: from heart attacks to Alzheimer's disease
Raffai and Weisgraber
J. Lipid Res. 2003;44:1423-1430.
ABSTRACT | FULL TEXT  

Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients
Baskin et al.
Neurology 2003;60:2006-2007.
ABSTRACT | FULL TEXT  

Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal
Dietschy and Turley
J. Lipid Res. 2004;45:1375-1397.
ABSTRACT | FULL TEXT